Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4

Gut

Volumn 64, Issue 12, 2015, Pages 1889-1897

  Zeissig, Sebastian ^a,b   Petersen, Britt Sabina ^c   Tomczak, Michal ^b   Melum, Espen ^b,d   Huc Claustre, Emilie ^a   Dougan, Stephanie K ^b   Laerdahl, Jon K ^d,e   Stade, Björn ^c   Forster, Michael ^c   Schreiber, Stefan ^a,c   Weir, Dascha ^f   Leichtner, Alan M ^f   Franke, Andre ^c   Blumberg, Richard S ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF KIEL   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TYROSINE; CTLA4 PROTEIN, HUMAN;

ANTIGEN BINDING; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CLINICAL FEATURE; COMPUTER MODEL; CONTROLLED STUDY; CROHN DISEASE; EXOME; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MISSENSE MUTATION; MOLECULAR EVOLUTION; PENETRANCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOLESCENT; AUTOIMMUNE DISEASE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CHILD; COMPLICATION; CYTOTOXIC T LYMPHOCYTE; DIMERIZATION; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; FEMALE; GENETICS; HEK293 CELL LINE; HETEROZYGOTE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; ONSET AGE; PEDIGREE; PROTEIN MULTIMERIZATION; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; ANTIGENS, CD80; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CHILD; CROHN DISEASE; CTLA-4 ANTIGEN; DIABETES MELLITUS, TYPE 1; DIMERIZATION; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; HEK293 CELLS; HETEROZYGOTE; HUMANS; IMMUNOLOGIC MEMORY; MUTATION, MISSENSE; PEDIGREE; PENETRANCE; PROTEIN MULTIMERIZATION; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 84953427271     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308541     Document Type: Article

References (55)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-17.
2. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
3. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491: 119-24.
5. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795-805.
6. Uhlig HH, Schwerd T, Koletzko S, et al.; COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014.
7. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1.
8. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
9. Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011;34:566-78.
10. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:546-58.
11. Olszak T, Neves JF, Dowds CM, et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 2014;509:497-502.
12. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.
13. Glocker EO, Frede N, Perro M, et al. Infant colitis-it's in the genes. Lancet 2010;376:1272.
14. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012;143:347-55.
15. Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis 2013;19:115-23.
16. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011;106:1544-55.
17. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011;32:428-33.
18. Chambers CA, Cado D, Truong T, et al. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 1997;94:9296-301.
19. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
20. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
21. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9.
22. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-7.
23. Stade B, Seelow D, Thomsen I, et al. GrabBlur-a framework to facilitate the secure exchange of whole-exome and -genome SNV data using VCF files. BMC Genomics 2014;15(Suppl 4):S8.
24. Abecasis GR, Altshuler D, Auton A, et al.; 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.
25. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-14.
26. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
27. Fuentes Fajardo KV, Adams D, Program NCS, et al. Detecting false-positive signals in exome sequencing. Hum Mutat 2012;33:609-13.
28. Forster M, Forster P, Elsharawy A, et al. From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software. Nucleic Acids Res 2013;41:e16.
29. Notarangelo LD, Fischer A, Geha RS, et al.; International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009;124:1161-78.
30. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011;2:54.
31. Zeissig Y, Petersen BS, Milutinovic S, et al. XIAP variants in male Crohn's disease. Gut 2014.
32. Zeissig S, Dougan SK, Barral DC, et al. Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest 2010;120:2889-99.
33. Krieg A, Correa RG, Garrison JB, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA 2009;106:14524-9.
34. Lo HS, Wang Z, Hu Y, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003;13:1855-62.
35. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 2003;112:1437-43.
36. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
37. Hastbacka J, de la Chapelle A, Mahtani MM, et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell 1994;78:1073-87.
38. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997;82:4130-2.
39. Marron MP, Raffel LJ, Garchon HJ, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997;6:1275-82.
40. Nistico L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Human molecular genetics 1996;5:1075-80.
41. Lee YH, Kim JH, Seo YH, et al. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol 2014;75:414-21.
42. Chen Z, Brant SR, Li C, et al. CTLA4-1661A/G and 3'UTR long repeat polymorphisms are associated with ulcerative colitis and influence CTLA4 mRNA and protein expression. Genes and immunity 2010;11:573-83.
43. Assis S, Marques CR, Silva TM, et al. IL10 single nucleotide polymorphisms are related to upregulation of constitutive IL-10 production and susceptibility to Helicobacter pylori infection. Helicobacter 2014;19:168-73.
44. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's Disease and Ulcerative Colitis. Gastroenterology 2012;143:62-9.e4.
45. Kataoka H, Takahashi S, Takase K, et al. CD25(+)CD4(+) regulatory T cells exert in vitro suppressive activity independent of CTLA-4. Int Immunol 2005;17:421-7.
46. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10.
47. Tang Q, Boden EK, Henriksen KJ, et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004;34:2996-3005.
48. Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 2014;123:1989-99.
49. Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
50. Maurer M, Loserth S, Kolb-Maurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002;54:1-8.
51. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.
52. Pesu M, Watford WT, Wei L, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008;455:246-50.
53. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
54. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998;187:571-8.
55. Stamper CC, Zhang Y, Tobin JF, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001;410:608-11.